Lonza Acquires Biotech Service Provider Algonomics
Lonza integrates Innovative Technology in its Protein Design Services offering
Lonza strengthens its protein design technology offering for biopharmaceutical development by acquiring Algonomics NV. Algonomics is a contract research organisation providing integrated immunogenicity prediction services to support companies in the development of biotherapeutics. Effective 2 November 2009 Lonza has acquired all shares of Algonomics including the proprietary Epibase, Epibase IV and Tripole technology platforms as well as the existing services business. The purchase price was not disclosed.
“The acquisition of this business is in line with our goal to offer a compelling portfolio of services and technologies for the creation, optimization and development of advanced, best in class biopharmaceuticals”, said Janet White, Head of Lonza Development Services & Biologics R&D. “With the combined technologies of Lonza and Algonomics we can significantly strengthen our offering for our customers”.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Eavesdropping on bacterial conversations may improve chronic wound healing

QX600 Droplet Digital PCR System | Droplet Digital PCR systems | Bio-Rad Laboratories

ASSIST PLUS | Pipetting robots | Integra Biosciences
Metabolic fingerprints offer fresh clues and a new path toward personalized medicine

Hope in the fight against cancer: They build proteins that are not known to nature - Basel-based biotech startup has big ideas for the future: it aims to take protein engineering into a new era

Ultra-long protein fibrils give clues on dementia risk - "AFM technology has the potential to complement conventional biomarker tests and improve the early detection of Alzheimer's"
GLOBAL BIOENERGIES and AUDI continue partnership in renewable gasoline
The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market
Evotec expands collaboration with MedImmune, receives milestone payment

Water-Soluble Warped Nanographene - Synthesis of a water-soluble warped nanographene and its application for photo-induced cell death
